Marketing and globalising biosimilars in a competitive landscape

Journal of Generic Medicines

Volumn 3, Issue 2, 2006, Pages 115-120

  Harris, James ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; HUMAN GROWTH HORMONE; HUMAN INSULIN; INTERFERON BETA SERINE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT DNA; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT HEPATITIS B VACCINE;

ARTICLE; BIOEQUIVALENCE; COMPETITION; DECISION MAKING; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MARKETING; DRUG PURIFICATION; DRUG SAFETY; DRUG STRUCTURE; ECONOMIC DEVELOPMENT; GENE EXPRESSION SYSTEM; PATENT; PRACTICE GUIDELINE; QUANTITATIVE ANALYSIS; STRUCTURE ANALYSIS;

EID: 33751579434     PISSN: 17411343     EISSN: 17417090     Source Type: Journal    
DOI: 10.1057/palgrave.jgm.4940108     Document Type: Article

References (7)

1. URL: http://www.gphaonline.com/.
2. URL: http://www.emea.eu.int/.
3. Directive 2001/83/EC as amended.
4. Part II of Annex I of Directive 2001/83/EC as amended.
5. Guideline on similar biological medicinal products (CHMP/437/04/).
6. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances.
7. PPR Communications, a division of IMS (URL: http://open.imshealth.com/ webshop2IMSinclude/i_article_20040518b.asp).